Proteome pulls out of prostate test
Tuesday, 15 July, 2008
Proteome Systems [ASX: PXL] has stopped development of a prostate cancer diagnostics test, after concluding that bringing the product to market would take too long.
Proteome had discovered cancerous prostate tissues demonstrate increased expression of Human Carcinoma Antigen [HCA], and developed an assay for detection of HCA in semen samples.
But the company concluded that developing the assay for commercialisation would take too long and consume too many resources.
A spokesperson for the company said Proteome was committed to projects with near-term revenue potential.
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
